Rani Therapeutics Holdings, Inc.
RANIRani Therapeutics Holdings, Inc. in brief
Rani Therapeutics Holdings, Inc. is a listed company in the Biotechnology industry, based in San Jose, California, USA. It was founded in 2012. Its market value was $110 M on 22 September 2026, which makes it the 18,388th largest listed company in the world and the 3,476th largest in the USA on this site. In the year to December 2025 it had sales of $2 M and a net loss of $30 M. It employs about 69 people and Talat Imran is its chief executive. Its shares trade under the symbol RANI (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Rani Therapeutics Holdings, Inc.
We are a clinical stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. We are advancing a portfolio of oral therapeutics using our proprietary delivery technology and we are actively pursuing partnering the technology with third party biopharmaceutical companies for the oral delivery of their biologics and drugs.
Our technology comprises a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. We have two configurations of the platform – the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. We have completed three Phase 1 clinical trials using the RaniPill GO. We are also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200µL in liquid form with high bioavailability. We have tested preclinically the RaniPill HC with multiple therapeutics, including multiple different antibodies and peptides. In December 2025, we initiated a Phase 1 clinical trial with RT-114, a RaniPill HC capsule containing a GLP-1/GLP-2 dual agonist (PG-102), for the treatment of obesity.
From the company's annual report filed with the US SEC: read the report
Rani Therapeutics Holdings, Inc. timeline
- 2012
- 🏁· approximateFounded
- 2021
- 💰Record revenue of $3 millionFY2021, the highest of the 4 years on record.
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 2 August 2021; shares registered for exchange trading on 26 July 2021.
Events of Rani Therapeutics Holdings, Inc. from the company record, the company's financial years and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,377 (Jan 2022) · #3,185 (Dec 2022) · #3,539 (Jul 2023) · #3,384 (Jan 2024) · #1,801 (Mar 2026) · #3,429 (Aug 2026) · #3,489 (Sep 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 67.6×
- Price / book
- 3.3×
- Free cash flow yield
- -17.1%
- Net margin
- -1820.2%
- Operating margin
- -2350.3%
- Return on equity
- -89.9%
- Liabilities / assets
- 29.2%
- Net debt
- $-19M
- Revenue growth
- +58.3%
- R&D / revenue
- 1239.3%
- Revenue per employee
- $24 K
- Profit per employee
- $-430 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2M | +58.3% | $-38M | $-30M | -1820.2% |
| Dec 2024 | $1M | — | $-53M | $-30M | -2914.6% |
| Dec 2023 | — | — | $-66M | $-34M | — |
| Dec 2022 | — | — | $-63M | $-31M | — |
| Dec 2021 | $3M | +491.3% | $-52M | $-8M | -306.3% |
| Dec 2020 | $0M | — | $-17M | $-17M | -3630.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-19M | $0M | $-19M | $-0.45 | — |
| Dec 2024 | $-36M | $0M | $-36M | $-1.05 | — |
| Dec 2023 | $-51M | $1M | $-52M | $-1.33 | — |
| Dec 2022 | $-47M | $2M | $-48M | $-1.28 | — |
| Dec 2021 | $-32M | $1M | $-33M | $-0.43 | — |
| Dec 2020 | $-15M | $1M | $-16M | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue $2M, net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportListing notice
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Aug 4, 20268-KCurrent reportDirectors or officers changed
- Jun 30, 20268-KCurrent reportDirectors or officers changed
- May 29, 20268-KCurrent reportShareholder vote
- May 27, 20268-KCurrent reportOther events
- May 15, 202610-QQuarterly report · period to Mar 2026
- May 15, 20268-KCurrent reportResults of operations · Listing notice · Directors or officers changed
- Apr 16, 2026DEF 14AProxy statement
Official filings of Rani Therapeutics Holdings, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $2 M
- Operating income
- $-38 M
- Net income
- $-30 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $59 M
- Total liabilities
- $17 M
- Total equity
- $33 M
As of December-2025
Top 68 institutional investors in Rani Therapeutics Holdings, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Samsara Biocapital, LLC | 10,369,159 | 0 (0.00%) | 7.44% | $8 M | Nov 16, 2026 |
| 2 | Ra Capital Management, L.P. | 8,500,000 | 0 (0.00%) | 6.10% | $7 M | Nov 16, 2026 |
| 3 | AWM Investment Company, Inc. | 7,500,000 | 0 (0.00%) | 5.38% | $6 M | Nov 13, 2026 |
| 4 | Vanguard Capital Management LLC | 4,566,458 | +3,473 (+0.08%) | 3.28% | $4 M | Nov 13, 2026 |
| 5 | Longaeva Partners L.P. | 2,329,459 | 0 (0.00%) | 1.67% | $2 M | Nov 16, 2026 |
| 6 | Polar Asset Management Partners Inc. | 2,000,000 | -318,542 (-13.74%) | 1.44% | $2 M | Nov 16, 2026 |
| 7 | Siren, L.L.C. | 1,594,800 | -405,200 (-20.26%) | 1.15% | $1 M | Nov 12, 2026 |
| 8 | Gsa Capital Partners LLP | 1,049,321 | +799,605 (+320.21%) | 0.75% | $1 M | Nov 16, 2026 |
| 9 | Millennium Management LLC | 968,531 | New | 0.70% | $1 M | Nov 16, 2026 |
| 10 | Heights Capital Management, Inc | 934,580 | 0 (0.00%) | 0.67% | $1 M | Nov 16, 2026 |
| 11 | Geode Capital Management, LLC | 925,138 | +34,520 (+3.88%) | 0.66% | $1 M | Nov 6, 2026 |
| 12 | Citadel Advisors LLC | 751,381 | +109,386 (+17.04%) | 0.54% | $1 M | Nov 16, 2026 |
| 13 | Vanguard Fiduciary Trust Co | 547,007 | +88,881 (+19.40%) | 0.39% | $0 M | Nov 13, 2026 |
| 14 | Renaissance Technologies LLC | 540,540 | +109,803 (+25.49%) | 0.39% | $0 M | Nov 12, 2026 |
| 15 | Nan Fung Group Holdings Ltd | 493,584 | 0 (0.00%) | 0.35% | $0 M | Nov 13, 2026 |
| 16 | State Street Corp | 395,642 | +22,500 (+6.03%) | 0.28% | $0 M | Nov 12, 2026 |
| 17 | Nano Cap New Millennium Growth Fund L P | 362,500 | New | 0.26% | $0 M | Nov 13, 2026 |
| 18 | BlackRock, Inc. | 347,865 | +5,752 (+1.68%) | 0.25% | $0 M | Nov 13, 2026 |
| 19 | Marshall Wace, LLP | 329,132 | -257,133 (-43.86%) | 0.24% | $0 M | Nov 13, 2026 |
| 20 | United Services Automobile Association | 302,743 | 0 (0.00%) | 0.22% | $0 M | Nov 13, 2026 |
| 21 | Kestra Private Wealth Services, LLC | 290,376 | +8,036 (+2.85%) | 0.21% | $0 M | Nov 6, 2026 |
| 22 | UBS Group AG | 230,867 | -66,403 (-22.34%) | 0.17% | $0 M | Nov 10, 2026 |
| 23 | Susquehanna International Group, LLP | 179,167 | +121,377 (+210.03%) | 0.13% | $0 M | Nov 16, 2026 |
| 24 | Northern Trust Corp | 170,471 | 0 (0.00%) | 0.12% | $0 M | Nov 16, 2026 |
| 25 | CWA Asset Management Group, LLC | 150,000 | 0 (0.00%) | 0.11% | $0 M | Oct 19, 2026 |
Show all 68: investors 26 to 68
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Jane Street Group, LLC | 110,441 | -375,458 (-77.27%) | 0.08% | $0 M | Nov 12, 2026 |
| 27 | Citigroup Inc | 82,900 | +80,257 (+3036.59%) | 0.06% | $0 M | Nov 4, 2026 |
| 28 | King Luther Capital Management Corp | 58,000 | 0 (0.00%) | 0.04% | $0 M | Nov 5, 2026 |
| 29 | Well Done, LLC | 52,014 | 0 (0.00%) | 0.04% | $0 M | Oct 20, 2026 |
| 30 | Janney Montgomery Scott LLC | 49,200 | 0 (0.00%) | 0.04% | $0 M | Nov 12, 2026 |
| 31 | Motco | 48,129 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 32 | HRT Financial LP | 34,913 | New | 0.03% | $0 M | Nov 13, 2026 |
| 33 | Squarepoint Ops LLC | 32,420 | -9,482 (-22.63%) | 0.02% | $0 M | Nov 9, 2026 |
| 34 | Zurcher Kantonalbank (Zurich Cantonalbank) | 31,987 | +12,936 (+67.90%) | 0.02% | $0 M | Nov 10, 2026 |
| 35 | Vanguard Global Advisers, LLC | 31,751 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 36 | Morgan Stanley | 31,156 | +670 (+2.20%) | 0.02% | $0 M | Nov 13, 2026 |
| 37 | Bank Of America Corp /de/ | 31,073 | New | 0.02% | $0 M | Nov 16, 2026 |
| 38 | Lafayette Investments, Inc. | 22,979 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 39 | Traphagen Investment Advisors LLC | 22,024 | 0 (0.00%) | 0.02% | $0 M | Oct 14, 2026 |
| 40 | China Universal Asset Management Co., Ltd. | 21,061 | +3,174 (+17.74%) | 0.02% | $0 M | Oct 28, 2026 |
| 41 | Farallon Capital Management, L.L.C. | 20,700 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 42 | Cerity Partners LLC | 19,090 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 43 | Goldman Sachs Group Inc | 17,051 | +5,311 (+45.24%) | 0.01% | $0 M | Nov 16, 2026 |
| 44 | SBI Securities Co., Ltd. | 15,676 | +167 (+1.08%) | 0.01% | $0 M | Oct 22, 2026 |
| 45 | ACT Advisors, LLC. | 14,701 | -105 (-0.71%) | 0.01% | $0 M | Oct 15, 2026 |
| 46 | Bank of New York Mellon Corp | 13,879 | 0 (0.00%) | 0.01% | $0 M | Nov 5, 2026 |
| 47 | Farther Finance Advisors, LLC | 13,800 | 0 (0.00%) | 0.01% | $0 M | Oct 8, 2026 |
| 48 | Clear Wave Wealth Management LLC | 13,228 | 0 (0.00%) | 0.01% | $0 M | Nov 4, 2026 |
| 49 | Disciplined Investors, L.L.C. | 12,200 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 50 | Rockefeller Capital Management L.P. | 12,045 | +500 (+4.33%) | 0.01% | $0 M | Nov 13, 2026 |
| 51 | Sanctuary Advisors, LLC | 12,014 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 52 | Prime Capital Investment Advisors, LLC | 11,485 | 0 (0.00%) | 0.01% | $0 M | Oct 20, 2026 |
| 53 | Barclays PLC | 10,486 | +450 (+4.48%) | 0.01% | $0 M | Nov 6, 2026 |
| 54 | Tower Research Capital LLC (TRC) | 10,155 | -19,588 (-65.86%) | 0.01% | $0 M | Nov 16, 2026 |
| 55 | Cary Street Partners Financial LLC | 10,000 | -550 (-5.21%) | 0.01% | $0 M | Nov 12, 2026 |
| 56 | Jpmorgan Chase & Co | 6,284 | -837 (-11.75%) | 0.00% | $0 M | Nov 12, 2026 |
| 57 | Mirae Asset Global Investments Co., Ltd. | 5,898 | +872 (+17.35%) | 0.00% | $0 M | Oct 29, 2026 |
| 58 | Glass Jacobson Investment Advisors llc | 5,000 | New | 0.00% | $0 M | Oct 26, 2026 |
| 59 | Osaic Holdings, Inc. | 4,287 | +500 (+13.20%) | 0.00% | $0 M | Nov 12, 2026 |
| 60 | Group One Trading LLC | 4,285 | +561 (+15.06%) | 0.00% | $0 M | Nov 10, 2026 |
| 61 | Simplex Trading, LLC | 2,912 | -2,224 (-43.30%) | 0.00% | $0 M | Nov 4, 2026 |
| 62 | BNP Paribas Financial Markets | 1,830 | -304 (-14.25%) | 0.00% | $0 M | Nov 12, 2026 |
| 63 | Jones Financial Companies Lllp | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 64 | Smartleaf Asset Management LLC | 1,000 | New | 0.00% | $0 M | Nov 10, 2026 |
| 65 | Royal Bank Of Canada | 140 | +16 (+12.90%) | 0.00% | $0 M | Nov 16, 2026 |
| 66 | John Boyer, Inc. | 100 | New | 0.00% | $0 M | Oct 27, 2026 |
| 67 | Northwestern Mutual Wealth Management Co | 50 | -1,050 (-95.45%) | 0.00% | $0 M | Nov 13, 2026 |
| 68 | FMR LLC | 23 | New | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding Rani Therapeutics Holdings, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 3.65 M | $3 M | 3.1% | <0.01% | −1.5% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 834,894 | $1 M | 0.70% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 402,359 | $0 M | 0.34% | <0.01% | −0.0% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 138,177 | $0 M | 0.12% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 115,378 | $0 M | 0.10% | <0.01% | +3.2% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 114,500 | $0 M | 0.10% | 0.06% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 61,920 | $0 M | 0.05% | <0.01% | +25% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 49,891 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 31,501 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 479 | $0 M | <0.01% | <0.01% | −1.6% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Rani Therapeutics Holdings, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Alireza JavadiChief Technical Officer | Shares withheld for tax | -309 | $0.760 | $235 | 9,071 | Form 4 |
| filed | Talat ImranChief Executive Officer, Director | Shares withheld for tax | -7,928 | $0.760 | $6 K | 461,808 | Form 4 |
| filed | Mir A. ImranDirector, 10% owner | Buy | +36,000 | $0.690 | $25 K | 2.12 M | Form 4 |
| filed | Talat ImranChief Executive Officer, Director | Buy | +35,000 | $0.720 | $25 K | 469,736 | Form 4 |
| filed | Alireza JavadiChief Technical Officer | Shares withheld for tax | -309 | $0.740 | $229 | 9,380 | Form 4 |
| filed | Talat ImranChief Executive Officer, Director | Shares withheld for tax | -7,927 | $0.740 | $6 K | 434,736 | Form 4 |
| filed | Alireza JavadiChief Technical Officer | Sell | -386 | $0.780 | $301 | 9,689 | Form 4 |
| filed | Talat ImranChief Executive Officer, Director | Shares withheld for tax | -9,099 | $0.810 | $7 K | 442,663 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Rani Therapeutics Holdings, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-10-17 19:32 UTC, code LUDP, resumed 19:37 UTC
- 2025-10-17 16:14 UTC, code LUDP, resumed 16:19 UTC
- 2025-10-17 16:07 UTC, code LUDP, resumed 16:12 UTC
- 2025-10-17 15:55 UTC, code LUDP, resumed 16:00 UTC
- 2025-10-17 15:50 UTC, code LUDP, resumed 15:55 UTC
Fails to deliver
- : 81,101 shares at $0.79
- : 80 shares at $0.87
- : 5 shares at $0.86
- : 1,439 shares at $0.79
- : 55,228 shares at $0.70
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Rani Therapeutics Holdings, Inc. scorecard#
Passes 4 of the 18 checks that could be worked out: strongest in financial health (3 of 6), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Sep 22, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.3×Price to book 3.3× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median67.6×Price to sales 67.6× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-17.1%Free cash flow is -17.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 3
- ✓Revenue grew in the newest year58.2%Revenue up 58.2% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.45 vs -1.05Diluted EPS -0.45 in fiscal 2025 against -1.05 the year before (report's currency).
- ✗Net income higher than five years earlier-$30 M-$30 M in fiscal 2025 against -$17 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$30 MNet income -$30 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-169.5%-169.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 6
- ✓Short-term assets cover short-term liabilities4.2×Current ratio 4.21 at the end of fiscal 2025.
- ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $19 M at the end of fiscal 2025.
- ✗Operating income covers interest five times-13.3×Operating income -13.3 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-0.60Z-score -0.60 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year135.7%Diluted shares up 135.7% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Rani Therapeutics Holdings, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Return on equity | -169.5% | -61.0% | |
| Revenue growth | 58.3% | 15.8% | |
| Debt to equity | 0.00× | 0.26× |
4of 8on the Piotroski tests of financial strength
- Net loss of $30 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$19 million.
- The share count rose 135.7% in the year.
- Operating income covers the interest bill only -13.3 times.
Rani Therapeutics Holdings, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1.6+58.9%100% | 1.0—100% | 0—— | 0−100%— | 2.7+488%100% | 0.5—100% | |
| Research and development | 20−24.3%1237% | 27−32.7%2596% | 40+8.2%— | 37+38.2%— | 26+120%975% | 12—2607% | |
| General and administrative | 20−17.6%1209% | 24−9.6%2329% | 26−1.4%— | 27−3.6%— | 28+461%1024% | 5.0—1074% | |
| Operating expenses | 40−26.5%2446% | 54−17.8%5286% | 66+4.2%— | 63+16.8%— | 54r−54—1999% | −17—−3681% | |
| Operating income | −38—−2346% | −53—−5186% | −66—— | −63—— | −52—−1899% | −17—−3581% | |
| Interest and finance income | — | — | — | — | 0.1+41.3%3.3% | 0.1—13.6% | |
| Interest expense and finance costs | 2.9−42.6%177% | 5.0−1.0%490% | 5.1+375%— | 1.1+130%— | 0.5+276%17.2% | 0.1—26.8% | |
| Income before tax | — | — | −68—— | −63—— | −53—−1952% | −17—−3608% | |
| Income tax | 0—0.0% | 0—0.0% | 0−100%— | 0.1+70.7%— | 0.0+17.1%1.5% | 0.0—7.6% | |
| Net income including minority interests | −41—−2508% | −57—−5504% | −68—— | −63—— | −53—−1954% | −17—−3615% | |
| Minority interests' share of net income | −11—−691% | −27—−2584% | −34—— | −33—— | −45—−1647% | −17—−3615% | |
| Net income attributable to shareholders | −30—−1817% | −30—−2920% | −34—— | −31—— | −8.3—−307% | — | |
| Earnings per share, basic | -0.45—— | -1.05—— | -1.33—— | -1.28—— | -0.43—— | — | |
| Earnings per share, diluted | -0.45—— | -1.05—— | -1.33—— | -1.28—— | -0.43—— | — | |
| Shares, weighted average (basic) | 0.1+132%— | 0.0+11.6%— | 0.0+7.1%— | 0.0+21.9%— | 0.0—— | — | |
| Shares, weighted average (diluted) | 0.1+132%— | 0.0+11.6%— | 0.0+7.1%— | 0.0+21.9%— | 0.0r20—— | — | |
| Balance sheet | |||||||
| Cash and cash equivalents | 19+395%31.8% | 3.8−35.8%10.3% | 5.9−78.3%10.1% | 27−77.0%25.0% | 117+60.8%94.6% | 73—92.0% | |
| Short-term investments | — | — | — | 99—91.2% | — | — | |
| Receivables | 2.0—3.5% | 0—0.0% | — | — | — | — | |
| Other current assets | — | — | — | — | 2.1—1.7% | — | |
| Current assets | 53+79.3%91.0% | 30−41.5%81.2% | 51−49.6%87.8% | 101−15.6%93.4% | 120+59.6%96.3% | 75—94.4% | |
| Property, plant and equipment | 0.7−52.5%1.3% | 1.5−74.6%4.2% | 6.1+1.1%10.5% | 6.0+30.9%5.6% | 4.6+3.2%3.7% | 4.5—5.6% | |
| Right-of-use (leased) assets | 4.3−15.3%7.4% | 5.1+610%13.9% | 0.7−32.6%1.2% | 1.1—1.0% | 0—0.0% | — | |
| Total assets | 59+60.0%100% | 37−36.7%100% | 58−46.4%100% | 108−13.0%100% | 124+56.4%100% | 79—100% | |
| Accounts payable | 0.3−77.3%0.5% | 1.4+110%3.7% | 0.6−55.6%1.1% | 1.5+35.2%1.4% | 1.1+101%0.9% | 0.5—0.7% | |
| Debt due within a year | 0−100%0.0% | 15+206%40.9% | 4.9—8.5% | 0—0.0% | — | 1.4—1.7% | |
| Current liabilities | 13−36.3%21.6% | 20+149%54.3% | 8.0+65.9%13.8% | 4.8+82.4%4.5% | 2.6−50.3%2.1% | 5.3—6.7% | |
| Long-term debt | 0−100%0.0% | 9.6−60.7%26.2% | 24−16.0%42.3% | 29—27.0% | 0−100%0.0% | 2.4—3.0% | |
| Lease liabilities (non-current) | 2.7−24.9%4.7% | 3.6—9.9% | 0−100%0.0% | 0.1—0.1% | 0—0.0% | — | |
| Total liabilities | 17−48.4%29.2% | 33+2.1%90.5% | 32−4.6%56.1% | 34+1189%31.5% | 2.6−67.2%2.1% | 8.0—10.1% | |
| Retained earnings | −133—−226% | −103—−281% | −73—−126% | −39—−36.0% | −8.3—−6.7% | −114—−144% | |
| Shareholders' equity | 33+1557%56.3% | 2.0−84.5%5.4% | 13−65.1%22.2% | 37−22.3%34.1% | 47—38.2% | −113—−143% | |
| Minority interests | 8.5+466%14.5% | 1.5−88.1%4.1% | 13−66.1%21.7% | 37−49.9%34.4% | 74—59.7% | 0—0.0% | |
| Total equity | 42+1088%70.8% | 3.5−86.3%9.5% | 25−65.6%43.9% | 74−39.1%68.5% | 122—97.9% | −113—−143% | |
| Total liabilities and equity | 59+60.0%100% | 37−36.7%100% | 58−46.4%100% | 108−13.0%100% | 124+56.4%100% | 79—100% | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.9−12.5%55.1% | 1.0+25.1%100% | 0.8+50.0%— | 0.5+10.3%— | 0.5—18.3% | — | |
| Share-based compensation | 12−26.4%722% | 16−15.7%1559% | 19+20.4%— | 16−30.2%— | 23—832% | 0—0.0% | |
| Cash from operating activities | −19—−1146% | −35—−3453% | −51—— | −47—— | −32—−1187% | −15—−3238% | |
| Capital expenditure | −0.1—−5.4% | −0.3—−26.1% | −1.2—— | −1.6—— | −0.5—−18.6% | −1.2—−260% | |
| Cash from investing activities | −7.0−135%−430% | 20−33.7%1927% | 30—— | −72—— | −0.5—−18.6% | −1.2—−260% | |
| Debt repaid | −21—−1269% | −5.0—−486% | 0—— | — | — | — | |
| Shares issued | — | — | — | — | 71—2617% | — | |
| Cash from financing activities | 40+197%2468% | 14+5730%1321% | 0.2−99.2%— | 29−62.4%— | 77+6.1%2839% | 73—15732% | |
| Change in cash | 15—891% | −2.1—−204% | −21—— | −90−303%— | 44−21.5%1634% | 57—12234% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 6.6+449%100% | 1.7—100% | 1.7—100% | 1.7+893%100% | 1.5*+42.1%100% | 0—— | 0—— | 0.2—100% | 1.0*—100% | 0—— | 0—— | 0—— | — | |
| Research and development | 21−4.5%321% | 6.0+86.9%353% | 5.0−8.9%294% | 5.2−21.4%302% | 4.9*−27.9%336% | 3.2−47.8%— | 5.5−10.0%— | 6.6−13.4%3820% | 6.8*−10.5%662% | 6.2—— | 6.1—— | 7.6—— | 7.6*—— | |
| General and administrative | 20+1.4%310% | 4.9+21.6%288% | 5.5+10.4%323% | 4.9−13.0%286% | 5.1*−6.9%348% | 4.0−28.3%— | 5.0−22.0%— | 5.6−12.9%3265% | 5.5*−6.3%531% | 5.6—— | 6.4—— | 6.4—— | 5.8*—— | |
| Operating expenses | 42−9.6%630% | 11+50.6%640% | 11+0.3%617% | 10−17.5%588% | 10.0*−37.5%684% | 7.3−38.5%— | 11−16.1%— | 12−13.2%7084% | 16*+19.0%1555% | 12—— | 13—— | 14—— | 13*—— | |
| Operating income | −35—−530% | −9.2—−540% | −8.8—−517% | −8.3—−488% | −8.5*—−584% | −7.3—— | −11—— | −12—−6984% | −15*—−1455% | −12—— | −13—— | −14—— | −13*—— | |
| Interest expense and finance costs | 0.5−86.8%7.4% | 0.0−94.1%2.5% | 0.0−99.1%0.5% | 0.1−90.7%5.2% | 0.3*−69.1%23.8% | 0.7−45.8%— | 0.9−31.3%— | 0.9−27.1%548% | 1.1*−13.3%109% | 1.3—— | 1.3—— | 1.3—— | 1.3*—— | |
| Income before tax | — | — | — | — | — | — | — | — | — | — | — | — | −14*—— | |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Net income including minority interests | −34—−521% | −8.8—−516% | −8.4—−493% | −8.0—−469% | −9.1*—−621% | −7.9—— | −11—— | −13—−7406% | −16*—−1529% | −13—— | −13—— | −15—— | −14*—— | |
| Minority interests' share of net income | −1.9—−28.2% | −1.1—−63.1% | −1.0—−60.3% | −1.0—−57.5% | 1.2*—84.3% | −2.5—— | −4.5—— | −5.5—−3183% | −6.8*—−659% | −5.9—— | −6.6—— | −7.3—— | −7.0*—— | |
| Net income attributable to shareholders | −32—−493% | −7.7—−453% | −7.4—−433% | −7.0—−412% | −10*—−705% | −5.4—— | −6.7—— | −7.3—−4223% | −8.9*—−870% | −6.8—— | −6.8—— | −7.5—— | −7.1*—— | |
| Earnings per share, basic | — | -0.04—— | -0.04—— | -0.04—— | — | -0.12—— | -0.18—— | -0.22—— | — | -0.24—— | -0.26—— | -0.29—— | — | |
| Earnings per share, diluted | — | -0.04—— | -0.04—— | -0.04—— | — | -0.12—— | -0.18—— | -0.22—— | — | -0.24—— | -0.26—— | -0.29—— | — | |
| Shares, weighted average (basic) | 199+328%— | 199+328%— | 187+412%— | 180+438%— | — | 46+61.1%— | 37+38.8%— | 33+28.4%— | — | 29—— | 26—— | 26—— | — | |
| Shares, weighted average (diluted) | 199+328%— | 199+328%— | 187+412%— | 180+438%— | — | 46+61.1%— | 37+38.8%— | 33+28.4%— | — | 29—— | 26—— | 26—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 3.6—6.9% | 3.6−12.6%6.9% | 4.9−52.3%8.0% | 9.6−4.6%18.6% | 19+395%31.8% | 4.1−3.1%40.9% | 10+126%60.5% | 10+47.0%41.9% | 3.8−35.8%10.3% | 4.3—9.8% | 4.5—10.3% | 6.9—12.9% | 5.9—10.1% | |
| Receivables | 2.0—3.7% | 2.0—3.7% | 2.0—3.4% | 2.0+240%3.9% | 2.0—3.5% | — | — | 0.6—2.5% | 0—0.0% | — | — | — | — | |
| Current assets | 48—92.3% | 48+878%92.3% | 57+410%92.9% | 47+165%90.8% | 53+79.3%91.0% | 5.0−84.7%48.9% | 11−65.4%65.5% | 18−57.0%73.7% | 30−41.5%81.2% | 32—74.3% | 32—73.3% | 41—77.3% | 51—87.8% | |
| Property, plant and equipment | 0.7—1.3% | 0.7−28.5%1.3% | 0.5−54.1%0.9% | 0.6−55.4%1.2% | 0.7−52.5%1.3% | 0.9−83.2%9.1% | 1.1−79.9%6.8% | 1.3−77.2%5.6% | 1.5−74.6%4.2% | 5.5—12.6% | 5.7—13.0% | 5.9—11.0% | 6.1—10.5% | |
| Right-of-use (leased) assets | 3.1—6.0% | 3.1−21.7%6.0% | 3.5−19.1%5.8% | 3.9−17.0%7.6% | 4.3−15.3%7.4% | 4.0−26.0%39.6% | 4.4−23.7%26.0% | 4.7−20.5%19.7% | 5.1+610%13.9% | 5.4—12.5% | 5.8—13.2% | 6.0—11.2% | 0.7—1.2% | |
| Total assets | 53—100% | 53+418%100% | 61+260%100% | 52+115%100% | 59+60.0%100% | 10−76.7%100% | 17−61.4%100% | 24−54.9%100% | 37−36.7%100% | 44—100% | 44—100% | 54—100% | 58—100% | |
| Accounts payable | 0.5—0.9% | 0.5−81.6%0.9% | 1.0−41.7%1.7% | 0.9−43.6%1.7% | 0.3−77.3%0.5% | 2.5+57.5%24.3% | 1.8+255%10.6% | 1.5+88.6%6.3% | 1.4+110%3.7% | 1.6—3.6% | 0.5—1.2% | 0.8—1.5% | 0.6—1.1% | |
| Debt due within a year | — | — | — | — | 0−100%0.0% | 14−8.3%134% | 15+22.1%88.8% | 15+74.7%62.2% | 15+206%40.9% | 15—33.9% | 12—28.1% | 8.6—16.0% | 4.9—8.5% | |
| Current liabilities | 9.2—17.6% | 9.2−51.8%17.6% | 11−48.4%17.5% | 14−31.2%26.7% | 13−36.3%21.6% | 19−5.3%189% | 21+24.4%122% | 20+50.5%83.4% | 20+149%54.3% | 20—46.4% | 17—37.9% | 13—25.0% | 8.0—13.8% | |
| Long-term debt | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 2.2−87.0%13.2% | 5.9−71.6%24.5% | 9.6−60.7%26.2% | 14—31.1% | 17—39.4% | 21—39.0% | 24—42.3% | |
| Lease liabilities (non-current) | 2.0—3.7% | 2.0−34.2%3.7% | 2.2−30.6%3.6% | 2.5−27.5%4.8% | 2.7−24.9%4.7% | 3.0−26.1%29.3% | 3.2−27.1%18.9% | 3.4−27.9%14.2% | 3.6—9.9% | 4.0—9.2% | 4.4—10.0% | 4.7—8.9% | 0—0.0% | |
| Total liabilities | 11—21.3% | 11−49.5%21.3% | 13−50.6%21.1% | 16−44.6%31.5% | 17−48.4%29.2% | 22−41.4%218% | 26−31.8%154% | 29−24.4%122% | 33+2.1%90.5% | 38—86.7% | 38—87.3% | 39—72.8% | 32—56.1% | |
| Retained earnings | −155—−295% | −155—−295% | −147—−242% | −140—−269% | −133—−226% | −122—−1206% | −117—−692% | −110—−457% | −103—−281% | −94—−216% | −87—−199% | −80—−150% | −73—−126% | |
| Shareholders' equity | 34—64.7% | 34—64.7% | 39—64.5% | 28—54.8% | 33+1557%56.3% | −7.9−352%−77.5% | −5.6−297%−33.0% | −3.1−141%−12.7% | 2.0−84.5%5.4% | 3.1—7.2% | 2.8—6.5% | 7.4—13.8% | 13—22.2% | |
| Minority interests | 7.4—14.1% | 7.4—14.1% | 8.8—14.4% | 7.1—13.8% | 8.5+466%14.5% | −4.1−255%−40.6% | −3.6−232%−21.2% | −2.3−132%−9.5% | 1.5−88.1%4.1% | 2.7—6.1% | 2.7—6.2% | 7.1—13.3% | 13—21.7% | |
| Total equity | 41—78.7% | 41—78.7% | 48—78.9% | 36—68.5% | 42+1088%70.8% | −12−307%−118% | −9.2−265%−54.2% | −5.3−137%−22.2% | 3.5−86.3%9.5% | 5.8—13.3% | 5.6—12.7% | 15—27.2% | 25—43.9% | |
| Total liabilities and equity | 53—100% | 53+418%100% | 61+260%100% | 52+115%100% | 59+60.0%100% | 10−76.7%100% | 17−61.4%100% | 24−54.9%100% | 37−36.7%100% | 44—100% | 44—100% | 54—100% | 58—100% | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.6−36.5%9.4% | 0.1*−44.8%7.2% | 0.2*−36.7%8.9% | 0.2−35.9%9.4% | 0.2*−30.1%12.7% | 0.2*−13.9%— | 0.2*−5.9%— | 0.3+1.2%146% | 0.3*+17.2%25.9% | 0.3*—— | 0.3*—— | 0.2—— | 0.2*—— | |
| Share-based compensation | 9.0−33.9%136% | 2.2*−5.5%130% | 2.4*−26.4%142% | 2.1−46.9%122% | 2.2*−43.9%153% | 2.3*−42.0%— | 3.3*−20.3%— | 3.9+1.4%2282% | 4.0*−11.0%388% | 4.0*—— | 4.1*—— | 3.9—— | 4.5*—— | |
| Cash from operating activities | −23—−349% | −7.8*—−455% | −9.0*—−528% | −6.5—−380% | 0.3*—20.1% | −5.1*—— | −5.8*—— | −8.1—−4738% | −8.7*—−842% | −8.4*—— | −9.0*—— | −9.4—— | −12*—— | |
| Capital expenditure | −0.2—−3.5% | −0.2*—−10.7% | −0.0*—−1.9% | −0.0—−0.9% | 0*—0.0% | 0*—— | −0.0*—— | −0.1—−29.7% | −0.0*—−3.0% | −0.1*—— | −0.1*—— | −0.0—— | −0.2*—— | |
| Cash from investing activities | −41−255%−625% | 6.9*—402% | −15*−355%−852% | −2.5−113%−143% | −31*−1329%−2120% | 0*−100%— | 5.7*−12.4%— | 18+77.1%10598% | 2.5*−81.0%245% | 0.5*—— | 6.5*—— | 10—— | 13*—— | |
| Debt repaid | −9.5—−144% | 0*—0.0% | 0*—0.0% | 0—0.0% | −9.5*—−648% | −3.8*—— | −3.8*—— | −3.8—−2180% | −3.8*—−365% | −1.3*—— | 0*—— | 0—— | 0*—— | |
| Shares issued | — | −0.3*—−19.9% | — | — | — | 0*—— | — | — | — | — | — | — | — | |
| Cash from financing activities | 63+5831%961% | −0.3*—−20.3% | 19*+9903%1101% | −0.0—−1.6% | 45*+698%3070% | −1.0*−113%— | 0.2*+33.3%— | −3.7−3183%−2169% | 5.6*+5753%547% | 7.7*—— | 0.1*—— | 0.1—— | 0.1*—— | |
| Change in cash | −0.8—−12.5% | −1.2*—−73.1% | −4.8*−4649%−280% | −9.0−241%−525% | 14*—970% | −6.1*—— | 0.1*—— | 6.3+527%3691% | −0.5*−158%−50.1% | −0.2*—— | −2.4*—— | 1.0—— | 0.9*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Rani Therapeutics Holdings, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 4 · Auditor changed 2 · Directors and officers 5 · Material agreement 2 · Agreement ended 1 · New debt 1 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Delisting noticeDirectors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Agreement endedShareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2025 | $60 M | Private placement after listing | $50 to $250 million | 15 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Rani Therapeutics Holdings, Inc.#
2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $126 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Mechanical Engineer IIIMechanical Engineers | 1 | $132 K |
| Validation Engineer IIValidation Engineers | 1 | $120 K |
Where: San Jose, CA 2
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 2 | 2 | $126 K | 2 |
| FY2025 | 4 | 4 | $120 K | 4 |
| FY2024 | 4 | 4 | $141 K | 4 |
| FY2023 | 9 | 9 | $120 K | 10 |
| FY2022 | 4 | 4 | $123 K | 4 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Rani Therapeutics, LLC
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 25% of workforce | Restructuring planSEC 8-K | “The Restructuring provides for a reduction of the Company’s workforce by approximately 25%.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Rani Therapeutics Holdings, Inc. compares in Biotechnology
- Market cap$110 M · higher than 37% of 726
- Revenue$2 M · higher than 29% of 647
- Revenue growth58.3% · higher than 75% of 438
- Price / sales67.6× · lower than 14% of 339
- Price / book3.3× · lower than 44% of 534
- FCF yield-17.1% · higher than 47% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Rani Therapeutics Holdings, Inc.🇺🇸 | $110 M | — | — | +58.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Sep 22, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Rani Therapeutics Holdings, Inc.? Verify and update this profile — free
Show Rani Therapeutics Holdings, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.